Enfuvirtide
 | |
| Clinical data | |
|---|---|
| Trade names | Fuzeon |
| AHFS/Drugs.com | monograph |
| Pregnancy category | |
| Legal status | |
| Routes of administration | Subcutaneous (SC) |
| Pharmacokinetic data | |
| Bioavailability | 84.3% (SC) |
| Protein binding | 92% |
| Metabolism | Hepatic |
| Biological half-life | 3.8 hours |
| Excretion | unknown |
| Identifiers | |
| CAS Number |
159519-65-0  |
| ATC code | J05AX07 |
| PubChem | CID 16130199 |
| DrugBank |
DB00109 |
| ChemSpider |
16743716 |
| UNII |
19OWO1T3ZE  |
| KEGG |
D02499 |
| ChEBI |
CHEBI:608828 |
| ChEMBL |
CHEMBL525076 |
| NIAID ChemDB | 059486 |
| Chemical data | |
| Formula | C204H301N51O64 |
| Molar mass | 4492.1 g/mol |
| |
| |
| (what is this?) (verify) | |
Enfuvirtide (INN) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
Enfuvirtide therapy costs an estimated US$25,000 per year in the United States. Its cost and inconvenient dosing regimen are factors behind its use as a reserve, for salvage therapy in patients with multi-drug resistant HIV.
Structural formula
Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
History
Enfuvirtide originated at Duke University, where researchers formed a pharmaceutical company known as Trimeris. Trimeris began development on enfuvirtide in 1996 and initially designated it T-20. In 1999, Trimeris entered into partnership with Hoffmann-La Roche to complete the development of the drug. It was approved by the U.S. Food and Drug Administration (FDA) on March 13, 2003 as the first HIV fusion inhibitor, a new class of antiretroviral drugs. It was approved on the basis of two studies (TORO 1 and TORO 2) which compared the effect of optimized regimens of antiretroviral medication with and without the addition of enfuvirtide on serum viral load.
Pharmacology
Mechanism of action
Enfuvirtide works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected. A biomimetic peptide, enfuvirtide was designed to mimic components of the HIV-1 fusion machinery and displace them, preventing normal fusion. Drugs that disrupt fusion of virus and target cell are termed entry inhibitors or fusion inhibitors.
HIV binds to the host CD4+ cell receptor via the viral protein gp120; gp41, a viral transmembrane protein, then undergoes a conformational change that assists in the fusion of the viral membrane to the host cell membrane. Enfuvirtide binds to gp41 preventing the creation of an entry pore for the capsid of the virus, keeping it out of the cell.[1]
T20 is also an activator of the chemotactic factor receptor, formyl peptide receptor 1 (FPR1), and thereby activates phaogocytes and presumably other cells bearing this receptor (See Formyl peptide receptors section on FPR1 receptors).[2] The physiological significance of this activation is unknown.
Microbiology
Enfuvirtide is considered to be active against HIV-1 only. Low activity against HIV-2 isolates has been demonstrated in vitro.[3]
Variable susceptibility to enfuvirtide has been observed in clinical isolates, with acquired resistance the result of a mutated 10 amino acid motif in viral gp41. Primary resistance, however, has yet to be observed.[4]
Clinical use
Indications
Enfuvirtide is indicated for the treatment of HIV-1 infection, in combination therapy with other antiretrovirals, in patients where all other treatments have failed.[5]
Dosage forms
By virtue of its peptide nature, enfuvirtide is marketed in injectable form. The lyophilised enfuvirtide powder must be reconstituted by the patient and administered twice daily by subcutaneous injection. Due to the chronic nature of this kind of therapy, this dosage form may be a major problem for the patient's adherence to this drug regimen.[6]
Adverse effects
Common adverse drug reactions (≥1% of patients) associated with enfuvirtide therapy include: injection site reactions (pain, hardening of skin, erythema, nodules, cysts, itch; experienced by nearly all patients, particularly in the first week), peripheral neuropathy, insomnia, depression, cough, dyspnoea, anorexia, arthralgia, infections (including bacterial pneumonia) and/or eosinophilia. Various hypersensitivity reactions occur infrequently (0.1–1% of patients), symptoms of which include rash, fever, nausea, vomiting, chills, rigors, hypotension, elevated hepatic transaminases; and possibly more severe reactions including respiratory distress, glomerulonephritis and/or anaphylaxis – rechallenge is not recommended.[5]
References
- ↑ Lalezari, JP; Eron, JJ; Carlson, M; Cohen, C; Dejesus, E; Arduino, RC; Gallant, JE; Volberding, P; et al. (2003). "A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy". AIDS (London, England) 17 (5): 691–8. doi:10.1097/01.aids.0000050825.06065.84 (inactive 2015-01-12). PMID 12646792.
- ↑ Blood 93: 3885-3892
- ↑ Roche Products Pty Ltd. Fuzeon (Australian Approved Product Information). Dee Why (NSW): Roche; 2005.
- ↑ Greenberg, ML; Cammack, N (2004). "Resistance to enfuvirtide, the first HIV fusion inhibitor". Journal of antimicrobial chemotherapy 54 (2): 333–40. doi:10.1093/jac/dkh330. PMID 15231762.
- 1 2 Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3
- ↑ Klein, Richard (13 March 2003). "FDA approves Fuzeon". fda.gov. Retrieved 2 July 2011.